Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference
November 26 2019 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced that Amit
Rakhit, M.D., President and Chief Medical Officer, will participate
in an analyst-led fireside chat at the 31st Annual Piper Jaffray
Healthcare Conference on Wednesday, December 4, 2019, at 4:00 p.m.
EST. The conference will be held at the Lotte New York Palace Hotel
in New York City.
A live audio webcast of the discussion can be accessed through
the Events & Presentations section of the company's website
at investors.ovidrx.com. An archived replay will be available
on the company's website for two weeks following the live
event.
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited for the potential treatment of rare developmental and
epileptic encephalopathies (DEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman1ABkatie@1abmedia.com
(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024